In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 226 to 250 of 424

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
MRI-guided focused ultrasound subthalamotomy for treating Parkinson's	Interventional procedures guidance	12 December 2024
MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's	Interventional procedures guidance	12 December 2024
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]	Technology appraisal guidance	16 July 2025
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]	Technology appraisal guidance	TBC
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221	Technology appraisal guidance	21 May 2025
Nemolizumab for treating prurigo nodularis [ID6451]	Technology appraisal guidance	21 May 2025
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]	Technology appraisal guidance	28 June 2017
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]	Technology appraisal guidance	TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]	Technology appraisal guidance	TBC
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]	Technology appraisal guidance	17 July 2024
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]	Technology appraisal guidance	TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]	Technology appraisal guidance	TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]	Technology appraisal guidance	TBC
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]	Technology appraisal guidance	TBC
Non-invasive skin closure devices for surgical incisions (MT775)	Medical technologies guidance	TBC
Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome	Diagnostics guidance	19 December 2024
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]	Technology appraisal guidance	TBC
NY-ESO-1 T-cells for treating synovial sarcoma ID1286	Technology appraisal guidance	TBC
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]	Technology appraisal guidance	25 June 2025
Obesity: clinical assessment and management (QS update)	Quality standard	TBC

Results per page

10
25
50
All